Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
543
datasets available to search
ShareScore release 0.9.0
Dataset results
543 results for “Preeclampsia”
Plane wave ultrasound and OCT angiography of the eye in preeclampsia
<p>This study involves examination of ocular blood flow in human subjects in preeclampsia (PE). Both eyes were examined by plane-wave ultrasound and by optical coherence angiography (OCTA) within 72 hours of delivery. Ultrasound Doppler was used to assess flow velocity and resistance in the central retinal artery and vein, the short posterior ciliary arteries and the choroid. OCTA was used to assess vascular density in the superficial and deep retina and the choriocapillaris. Analysis included correlation with blood pressure, assessment of differences between normal and PE and correlation of ultrasound Doppler with OCTA vascular density.</p>
Biologically informed machine learning for identifying human placental cellular heterogeneity and preeclampsia discovery
<p>Single-cell transcripts of 20,518 placental cells and identified 12 major placental cell clusters were collected from the European Bioinformatics Institute (EBI; accession no. EGAS00001002449) (29). Based on the same parameters, we clustered and visualized highly similar cells using t-distribution random neighbourhood embedding (T-SNE) to identify 17 cell subpopulations. we selected nine placental cell clusters that have received more attention from biologists for our study according to the literature survey (Table 1). Considering the sample balance, 7178 single-cell transcriptome data were used to identify human placental cell subpopulations. The samples were randomly divided into a 4809-sample training set and a 2369-sample testing set. The same strategy was applied to split single-cell transcriptomic datasets from healthy and preeclampsia patients (EBI; accession no. EGAS00001002449), with 9852 samples (healthy 4705, preeclampsia 5147) in the training set and 5305 samples (healthy 2473, preeclampsia 2832) in the independent test set</p>
Single-cell datasets for preeclampsia
<p>The dataset is preeclampsia with data preprocessing.</p>
HtrA1 in placental cell models: A possible role in preeclampsia
<p class="MDPI17abstract"><span><strong>Background: </strong>The High temperature requirement A 1 (HtrA1) is a multidomain secretory protein with serine-protease activity involved in the regulation of many cellular processes in both physiological and pathological conditions. HtrA1 is normally expressed in human placenta, and its expression is higher in the first trimester compared to the third trimester, suggesting an important role of this serine protease in early phases of human placenta development. The aim of this study was to evaluate the functional role of HtrA1 in in vitro models of human placenta in order to define the role of this serine protease in preeclampsia (PE)</span></p> <p class="MDPI17abstract"><span><strong>Methods</strong>: BeWo, HTR8/SVneo and HUVEC cells expressing HtrA1 and showing a cytoplasm localization of HtrA1 were used as syncytiotrophoblast, cytotrophoblast and placental endothelium models respectively. Oxidative stress was induced treating BeWo and HTR8/SVneo cells with H<sub>2</sub>O<sub>2</sub> to mimic PE conditions in order to evaluate its effect on HtrA1 expression. In addition, HtrA1 overexpression and silencing experiments were performed to evaluate the effects on syncytialization, cell mobility and invasion processes. Finally, human recombinant HtrA1 treatments were performed to study the effects of exogenous HtrA1 on Endoglin, VEGFA, ERK1/2, NF-kB and PCNA that are molecules involved in PE onset </span></p> <p class="MDPI17abstract"><span><strong>Results</strong>: Our main data showed that the oxidative stress significantly increased HtrA1 expression in both BeWo and HTR8/SVneo cells. In addition, we demonstrated that HtrA1 has a pivotal role in cell motility and invasion processes. In particular, HtrA1 overexpression increased while HtrA1 silencing decreased cell motility and invasion in HTR8/SVneo cell model. Finally, we found that hrHtrA1 treatments of HUVEC did not alter the expression of the listed above molecules involved in PE onset; (4) Conclusions: In conclusion, our results suggest an important role of HtrA1 in regulating extravillous cytotrophoblast invasion and motility during early stage of placentation in the first trimester of gestation suggesting a key role of this serine protease in PE onset.</span></p>
Calcium fortification of water during pregnancy for the prevention of preeclampsia in a low-income setting: a cost-effectiveness analysis
<p>This database contains the model and the parameters of the study. It's is important to highlight that this is the first version of the model, and thus modifications are forthcoming. With the current database, the abstract is the following:</p> <p>Fortification of water with calcium during pregnancy is proposed as a suitable and promising intervention to increase calcium intake and prevent preeclampsia and eclampsia (PE/E). However, the evidence of the cost-effectiveness of this type of intervention is scarce. We conducted a model-based cost-effectiveness analysis to estimate the incremental cost-effectiveness ratio (ICER) of calcium pills and bottled water fortified with calcium, compared to the standard of care (defined as the use of MgSO4 as the standard treatment for PE/E), in the context of Nepal. Outcome measures were years of life gained (YLG) by mothers and newborns and healthcare costs. We considered a lifetime time horizon and health benefits were discounted at 3%. The cost-effectiveness threshold was set at the 2019 Nepal gross domestic product per capita (USD 1071). For calcium pills versus standard of care, ICER was USD 63 per YLG. By switching from calcium pills to bottled water fortified with calcium, the resulting ICER was USD 1702 per YLG. In conclusion, the bottle of water fortified with calcium was found not cost-effective at the defined threshold for Nepal. Complementary economic evidence adapted to other low-and middle income contexts is required to guide novel preventive interventions to improve maternal and child health based on the efficiency principle</p>
Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia
ClinicalTrials.gov study NCT02059135. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.
Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia
ClinicalTrials.gov study NCT03171480. IPD Sharing: NO. Countries: 1. Publications: 7.
High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention
ClinicalTrials.gov study NCT01355159. IPD Sharing: Not stated. Countries: 5. Publications: 5.
Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
ClinicalTrials.gov study NCT02147626. IPD Sharing: Not stated. Countries: 1. Publications: 6.
MSC Exosome Therapy for Post-Preeclampsia Endothelial Dysfunction
ClinicalTrials.gov study NCT07183384. IPD Sharing: YES. Countries: 1. Publications: 1.
Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor
ClinicalTrials.gov study NCT04392375. IPD Sharing: NO. Countries: 1. Publications: 1.
Efficacy Study of Digibind for Treatment of Severe Preeclampsia
ClinicalTrials.gov study NCT00158743. IPD Sharing: Not stated. Countries: 1. Publications: 8.
MitoQ to Improve Vascular Funciton in Preeclampsia
ClinicalTrials.gov study NCT07229261. IPD Sharing: YES. Countries: 0. Publications: 10.
Non-invasive Versus Invasive Blood Pressure Measurement in the Morbidly Obese Parturient With Severe Preeclampsia
ClinicalTrials.gov study NCT03222414. IPD Sharing: NO. Countries: 1. Publications: 1.
Restrictive Fluid Therapy in Severe Preeclampsia
ClinicalTrials.gov study NCT02214186. IPD Sharing: Not stated. Countries: 1. Publications: 14.
Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia
ClinicalTrials.gov study NCT06220721. IPD Sharing: YES. Countries: 1. Publications: 15.
Hypertension In Postpartum Preeclampsia Study
ClinicalTrials.gov study NCT03011567. IPD Sharing: YES. Countries: 1. Publications: 1.
Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)
ClinicalTrials.gov study NCT00135707. IPD Sharing: YES. Countries: 1. Publications: 18.
Early Prevention of Preeclampsia Study
ClinicalTrials.gov study NCT01547390. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Low Dose Aspirin for Preventing Intrauterine Growth Restriction and Preeclampsia in Sickle Cell Pregnancy (PIPSICKLE)
ClinicalTrials.gov study NCT05253781. IPD Sharing: YES. Countries: 1. Publications: 29.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.